Richiedi una copia del documento: Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer : final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Captcha code
Annulla